Abstract
Bone substitutes with osteoinductive and (or) osteogenic capacities are highly needed in clinical practice for treatment of patients with skeletal bone pathology. Gene-activated bone substitutes consisting of a scaffold and gene constructs belong to such materials. In this study, we made two proto-types of gene-activated bone substitutes based on octacalcium phosphate (OCP) granules and two variants of plasmid DNA - the system delivering single gene encoding vascular endothelial growth factor A-165 (VEGFA-165, pl-VEGFA) and the other plasmid carrying simultaneously VEGFA and gene of stromal-derived factor 1a (pl-VEGFA-SDF). All the materials were implanted to rabbits into the full-thickness parietal bone defects with diameter 10 mm, OCP without plasmid DNA we used as a control. Both gene-activated materials showed pronounced osteoinduction providing new bone formation in the central part of the defects and complete parietal bone repair by 90 days after surgery. In addition, we found newly formed bone level to be higher in pl-VEGFA-SDF group comparing with pl-VEGFA (p
Sign-in/Register to access full text options 
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
